29266-73-7

Upstream product

• 17342-08-4 (S)-Pyroglutaminol 

Downstream Products

• 1103883-55-1 (S)-1-benzoyl-5-(iodomethyl)pyrrolidin-2-one 
• 108-27-0 5-methylpyrrolidin-2-one 
• 1038924-61-6 (S)-5-biphenyl-4-ylmethylpyrrolidin-2-one 
• 138723-00-9 (2R,5R)-1-(Carbobenzyloxy)-2-(1-hydroxypropyl)-5-methylpyrrolidine 
• 138810-08-9 (2S,5R)-1-(Carbobenzyloxy)-2-(1-hydroxypropyl)-5-methylpyrrolidine 
• 138723-02-1 (2S,5R)-1-(Carbobenzyloxy)-2-(3-hydroxydecyl)-5-methylpyrrolidine 
• 138723-03-2 (2S,5R)-1-(Carbobenzyloxy)-2-(3-oxodecyl)-5-methylpyrrolidine 
• 138723-01-0 (2S,5R)-1-(Carbobenzyloxy)-2-(1-oxopropyl)-5-methylpyrrolidine 
• 216172-36-0 (S)-5,6-Dimethylene-hexahydro-pyrrolizin-3-one 
• 720712-02-7 (5R)-5-allylpyrrolidin-2-one 
• 82259-09-4 (5S)-(+)-5-(1-Prop-2-enyl)-2-pyrrolidinone 
• 21395-93-7 (R)-(+)-5-methyl-2-pyrrolidinon 
• 216172-25-7 (S)-5-[2-(4-tert-Butyl-phenoxymethyl)-buta-2,3-dienyl]-pyrrolidin-2-one 

Relevant academic research and scientific papers

NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE

Provided are a novel low-molecular-weight compound that suppresses production of induction type MMPs, particularly MMP-9, rather than production of hemostatic type MMP-2, as well as a prophylactic/therapeutic drug for autoimmune diseases or osteoarthritis. An amide derivative represented by the following formula (I) wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof.

ORGANIC COMPOUNDS

Compounds of the formula (I) are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, musculoskeletal, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

Copper(I) mediated cross-coupling of amino acid derived organozinc reagents with acid chlorides

This paper describes the development of a straightforward experimental protocol for copper-mediated cross-coupling of amino acid derived β-amido-alkylzinc iodides 1 and 3 with a range of acid chlorides. The present method uses CuCN·2LiCl as the copper source and for organozinc reagent 1 the methodology appears to be limited to reaction with more stable acid chlorides, providing the desired products in moderate yields. When applied to organozinc reagent 3, however, the protocol is more general and provides the products in good yields in all but one of the cases tested. The Royal Society of Chemistry 2006.